Your browser doesn't support javascript.
loading
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms.
Kalmbach, Sabrina; Grau, Michael; Zapukhlyak, Myroslav; Leich, Ellen; Jurinovic, Vindi; Hoster, Eva; Staiger, Annette M; Kurz, Katrin S; Weigert, Oliver; Gaitzsch, Erik; Passerini, Verena; Engelhard, Marianne; Herfarth, Klaus; Beiske, Klaus; Micci, Francesca; Möller, Peter; Bernd, Heinz-Wolfram; Feller, Alfred C; Klapper, Wolfram; Stein, Harald; Hansmann, Martin-Leo; Hartmann, Sylvia; Dreyling, Martin; Holte, Harald; Lenz, Georg; Rosenwald, Andreas; Ott, German; Horn, Heike.
Afiliação
  • Kalmbach S; Department of Clinical Pathology, Robert-Bosch Hospital, Stuttgart, Germany.
  • Grau M; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Zapukhlyak M; University of Tübingen, Tübingen, Germany.
  • Leich E; Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
  • Jurinovic V; Department of Medicine A, Department of Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
  • Hoster E; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center Main, Würzburg, Germany.
  • Staiger AM; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Kurz KS; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Weigert O; Department of Clinical Pathology, Robert-Bosch Hospital, Stuttgart, Germany.
  • Gaitzsch E; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Passerini V; University of Tübingen, Tübingen, Germany.
  • Engelhard M; Department of Clinical Pathology, Robert-Bosch Hospital, Stuttgart, Germany.
  • Herfarth K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Beiske K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Micci F; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Möller P; Department for Radiotherapy, University Hospital of Essen, Essen, Germany.
  • Bernd HW; Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
  • Feller AC; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Klapper W; KG Jebsen center for B cell malignancies, Oslo, Norway.
  • Stein H; Section for Cancer Cytogenetics, Oslo University Hospital, Oslo, Norway.
  • Hansmann ML; Institute of Pathology, University Hospital Ulm, Ulm, Germany.
  • Hartmann S; Hematopathology, Lübeck, Germany.
  • Dreyling M; Hematopathology, Lübeck, Germany.
  • Holte H; Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Lenz G; Pathodiagnostik Berlin, Berlin, Germany.
  • Rosenwald A; Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany.
  • Ott G; Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany.
  • Horn H; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Leukemia ; 37(10): 2058-2065, 2023 10.
Article em En | MEDLINE | ID: mdl-37563306
ABSTRACT
Knowledge on the pathogenesis of FL is mainly based on data derived from advanced/systemic stages of FL (sFL) and only small cohorts of localized FL (lFL) have been characterized intensively so far. Comprehensive analysis with profiling of somatic copy number alterations (SCNA) and whole exome sequencing (WES) was performed in 147 lFL and 122 sFL. Putative targets were analyzed for gene and protein expression. Overall, lFL and sFL, as well as BCL2 translocation-positive (BCL2+) and -negative (BCL2-) FL showed overlapping features in SCNA and mutational profiles. Significant differences between lFL and sFL, however, were detected for SCNA frequencies, e.g., in 18q-gains (14% lFL vs. 36% sFL; p = 0.0003). Although rare in lFL, gains in 18q21 were associated with inferior progression-free survival (PFS). The mutational landscape of lFL and sFL included typical genetic lesions. However, ARID1A mutations were significantly more often detected in sFL (29%) compared to lFL (6%, p = 0.0001). In BCL2 + FL mutations in KMT2D, BCL2, ABL2, IGLL5 and ARID1A were enriched, while STAT6 mutations more frequently occurred in BCL2- FL. Although the landscape of lFL and sFL showed overlapping features, molecular profiling revealed novel insights and identified gains in 18q21 as prognostic marker in lFL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article